Abstract
ABSTRACTSeventh pandemicVibrio choleraewas first identified in Cameroon in 1971, causing several sporadic disease clusters with few cases. More recent years have seen larger cholera outbreaks, but the mechanism behind these periodic outbreaks is poorly understood, and it is unclear the degree to which antibiotic resistant strains contribute to disease burden and spread. We used whole genome sequencing to characterize 14V. choleraeisolates from the 2020 and 2021-2023 cholera epidemics in Cameroon. All these isolates belonged to the T12 lineage, and most showed the same antimicrobial resistance (AMR) pattern regardless of year. This suggests that cholera outbreaks in Cameroon are, at least in part, a continuation of the outbreaks previously reported in 2018 and as far back as 2012. This finding has important implications for cholera management since it suggests the ongoing presence of pathogenic cholera even in years with few reported cases. Similarly, the AMR results suggest the need for new treatment approaches, as resistance to many common antibiotics was found even within our limited sample set. As such, whole genome sequencing should be implemented in low-income countries such as Cameroon to improve disease surveillance and to detect and predict pathogen antibiotic resistance profiles.
Publisher
Cold Spring Harbor Laboratory
Reference26 articles.
1. Origins of the current seventh cholera pandemic
2. Cholera outbreaks in Africa;Curr Top Microbiol Immunol,2014
3. Updated Global Burden of Cholera in Endemic Countries
4. UNICEF. Cholera epidemiology and response factsheet Cameroon. https://www.plateformecholera.info/attachments/article/220/UNICEF-Factsheet-Cameroon-EN-FINAL.pdf (2013, accessed 6 November 2023).
5. Rapport de Situation N°15, Épidémie de choléra dans la région de l’Extrême-Nord, 17 septembre 2019. Ministere De La Sante Publique. https://reliefweb.int/report/cameroon/rapport-de-situation-n-15-pid-mie-de-chol-ra-dans-la-r-gion-de-l-extr-me-nord-17 (x18 September 2019, accessed 22 November 2023).